IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse

BMC Musculoskeletal Disorders

Volumn 13, Issue , 2012, Pages

  Kostek, Matthew C ^a,d   Nagaraju, Kanneboyina ^b   Pistilli, Emidio ^b,c   Sali, Arpana ^b   Lai, San Huei ^b   Gordon, Brad ^a   Chen, Yi Wen ^b,e  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Laboratory of Muscle and Translational Therapeutics   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Duchenne; IL 6; Inflammation; Muscular dystrophy

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 10 MOUSE; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; MALE; MOUSE; MUSCLE FUNCTION; MUSCLE REGENERATION; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; NONHUMAN; PHENOTYPE; SIGNAL TRANSDUCTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RANDOM ALLOCATION; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84862326505     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-13-106     Document Type: Article

References (31)

1. Inflammatory processes in muscle injury and repair. Tidball JG, Am J Physiol Regul Integr Comp Physiol 2005 288 2 345 R353 15637171
2. Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Spencer MJ, Montecino-Rodriguez E, Dorshkind K, Tidball JG, Clin Immunol 2001 98 2 235 243 10.1006/clim.2000.4966 11161980
3. Two-tiered hypotheses for Duchenne muscular dystrophy. Grounds MD, Cell Mol Life Sci 2008 65 11 1621 1625 10.1007/s00018-008-7574-8 18327663
4. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Hodgetts S, Radley H, Davies M, Grounds MD, Neuromuscul Disord 2006 16 9-10 591 602 16935507
5. The role of corticosteroids in muscular dystrophy: a critical appraisal. Angelini C, Muscle Nerve 2007 36 4 424 435 10.1002/mus.20812 17541998
6. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Radley HG, Grounds MD, Neurobiol Dis 2006 23 2 387 397 10.1016/j.nbd.2006.03.016 16798005
7. Immunomodulation of TGF-beta 1 in mdx mouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. Andreetta F, Bernasconi P, Baggi F, Ferro P, Oliva L, Arnoldi E, Cornelio F, Mantegazza R, Confalonieri P, J Neuroimmunol 2006 175 1-2 77 86 16647144
8. Mast cells can modulate leukocyte accumulation and skeletal muscle function following hindlimb unloading. Dumont N, Lepage K, Cote CH, Frenette J, J Appl Physiol 2007 103 1 97 104 10.1152/japplphysiol.01132.2006 17395758
9. A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. Wehling M, Spencer MJ, Tidball JG, J Cell Biol 2001 155 1 123 131 10.1083/jcb.200105110 11581289
10. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. Acharyya S, Villalta SA, Bakkar N, Bupha-Intr T, Janssen PM, Carathers M, Li ZW, Beg AA, Ghosh S, Sahenk Z, et al. J Clin Invest 2007 117 4 889 901 10.1172/JCI30556 17380205
11. T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. Farini A, Meregalli M, Belicchi M, Battistelli M, Parolini D, D'Antona G, Gavina M, Ottoboni L, Constantin G, Bottinelli R, et al. J Pathol 2007 213 2 229 238 10.1002/path.2213 17668421
12. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Golumbek PT, Keeling RM, Connolly AM, Neuromuscul Disord 2007 17 5 376 384 10.1016/j.nmd.2007.02.005 17452104
13. Macrophages and skeletal muscle regeneration: a clodronate-containing liposome depletion study. Summan M, Warren GL, Mercer RR, Chapman R, Hulderman T, Van Rooijen N, Simeonova PP, Am J Physiol Regul Integr Comp Physiol 2006 290 6 1488 R1495 10.1152/ajpregu.00465.2005 16424086
14. Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth. Chazaud B, Sonnet C, Lafuste P, Bassez G, Rimaniol AC, Poron F, Authier FJ, Dreyfus PA, Gherardi RK, J Cell Biol 2003 163 5 1133 1143 10.1083/jcb.200212046 14662751
15. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, et al. Blood 2005 106 8 2627 2632 10.1182/blood-2004-12-4602 15998837
16. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, Cheung N, Williams B, Hazleman B, Price R, et al. Arthritis Rheum 2002 46 12 3143 3150 10.1002/art.10623 12483717
17. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, Woo P, Nishimoto N, Yoshizaki K, Kishimoto T, Arthritis Rheum 2005 52 3 818 825 10.1002/art.20944 15751095
18. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min/+) mouse. White JP, Baynes JW, Welle SL, Kostek MC, Matesic LE, Sato S, Carson JA, PLoS One 6 9 24650
19. Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Tsujinaka T, Ebisui C, Fujita J, Kishibuchi M, Morimoto T, Ogawa A, Katsume A, Ohsugi Y, Kominami E, Monden M, Biochem Biophys Res Commun 1995 207 1 168 174 10.1006/bbrc.1995.1168 7857261
20. Association of IGF-I levels with muscle strength and mobility in older women. Cappola AR, Bandeen-Roche K, Wand GS, Volpato S, Fried LP, J Clin Endocrinol Metab 2001 86 9 4139 4146 10.1210/jc.86.9.4139 11549640
21. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, Olivieri F, Giovagnetti S, Franceschi C, Guralnik JM, et al. Am J Physiol Endocrinol Metab 2003 284 3 481 E487 12419777
22. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. Tsujinaka T, Fujita J, Ebisui C, Yano M, Kominami E, Suzuki K, Tanaka K, Katsume A, Ohsugi Y, Shiozaki H, et al. J Clin Invest 1996 97 1 244 249 10.1172/JCI118398 8550842
23. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E, J Clin Invest 1997 99 4 643 650 10.1172/JCI119207 9045866
24. Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. Kurek JB, Nouri S, Kannourakis G, Murphy M, Austin L, Muscle Nerve 1996 19 10 1291 1301 10.1002/(SICI)1097-4598(199610)19: 10<1291::AID-MUS6>3.0.CO;2-9 8808655
25. Anabolic and catabolic biomarkers as predictors of muscle strength decline: the InCHIANTI study. Stenholm S, Maggio M, Lauretani F, Bandinelli S, Ceda GP, Di Iorio A, Giallauria F, Guralnik JM, Ferrucci L, Rejuvenation Res 13 1 3 11 20230273
26. Effect of rhIL-6 infusion on GH->IGF-I axis mediators in humans. Nemet D, Eliakim A, Zaldivar F, Cooper DM, Am J Physiol Regul Integr Comp Physiol 20 4 790 805 21118895
27. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S, Biochim Biophys Acta 1813 5 878 888
28. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Villalta SA, Nguyen HX, Deng B, Gotoh T, Tidball JG, Hum Mol Genet 111 6 1768 1777 21960659
29. How inflammation changes neuromuscular function and its relevance to symptoms in diverticular disease. Spiller R, J Clin Gastroenterol 2006 40 Suppl 3 117 S120 16885693
30. Inflammation at the neuromuscular junction in myasthenia gravis. Maselli RA, Richman DP, Wollmann RL, Neurology 1991 41 9 1497 1504 10.1212/WNL.41.9.1497 1891103
31. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A, Neurobiol Dis 2008 31 1 1 19 10.1016/j.nbd.2008.03.008 18499465